RxDoctor Payments Data

Jared Vincent, MD

Ophthalmology · Ruston, LANPI 1639167836

Payments from drug & device makers

$4,973in general payments, 2019–2025

Across 156 payments — averaging $31.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Glaukos Corporation$1K
  • Alcon$1K
  • AbbVie$747
  • Ocular Therapeutix, Inc.$408
  • Johnson & Johnson Surgical Vision, Inc.$298
  • Bausch & Lomb Americas Inc.$189
  • plus $760 from 14 others

What the payments were for

  • Food & beverage$4,93399%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,973 in reported general payments places this provider in the 75th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$120,352
Medicare patients
415
Services billed
1,105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine69$48,144
Prednisolone Acetate897$42,864
RocklatanNetarsudil Mesylat/Latanoprost92$35,073
LumiganBimatoprost55$25,369
VyzultaLatanoprostene Bunod25$12,976
CombiganBrimonidine Tartrate/Timolol39$12,164
SimbrinzaBrinzolamide/Brimonidine Tart50$10,966
RhopressaNetarsudil Mesylate21$7,013
Latanoprost797$6,320
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol42$5,757
Fluorometholone77$5,388
Cyclosporine19$4,673
MoxifloxacinMoxifloxacin Hcl110$4,319
Travoprost25$4,151
Ciprofloxacin Hcl327$3,849

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$747$85,677163 claims
Bausch & Lomb Americas Inc.Vyzulta$189$12,97625 claims
AlconSimbrinza$1,225$10,96650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in Ruston

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →